Merck KGaA suffers setback for cancer drug

September 18, 2012

German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.

Merck said in a statement it had decided to "voluntarily withdraw the marketing authorisation application to the European Medicines Agency" for to be used to treat patients with advanced or metastatic non-small cell lung cancer.

The decision was "based on feedback from European regulatory authorities, indicating that further data would be required," the statement said.

It would not affect, however, "the proven utility of Erbitux in its already approved indications in metastatic and ," Merck insisted.

"We are disappointed that we have not been able to move forward with the filing but it has become apparent that further data will be required to support the clinical utility of Erbitux in this specific population," said Merck's head of drug development, Annalisa Jenkins.

Already in July, Merck KGaA had said that phase III clinical trials of Erbitux for treatment of drug had shown no benefits of the drug for patients.

The news hit Merck KGaA shares which were showing a loss of 1.24 percent at 93.67 euros in mid-morning trade on the Frankfurt stock exchange in a generally softer market.

Explore further: Merck KGaA suffers setback on cancer drug

Related Stories

Merck KGaA suffers setback on cancer drug

July 5, 2012
German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.

Drug company Merck to cut 1 jobs in 10 in Germany

September 4, 2012
(AP)—German drug maker Merck KGaA is to eliminate one out of every 10 jobs in its home country.

New test helps evaluate cancer drug's merit

July 9, 2012
(HealthDay) -- A new genetic test to help doctors determine if the drug Erbitux would be an effective treatment for certain colorectal cancer patients has been approved by the U.S. Food and Drug Administration.

Recommended for you

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.